BioNTech

BioNTech’s Slide Has Little to Do With BioNTech

kashif hafeez -

BioNTech’s Shrinking Footprint: What the Factory Sale Talks and Sahin’s September Trades Say About the Pipeline Bet

Brett Shapiro -

BioNTech’s September Crossroads: A Pipeline Setback, a Factory Fire Sale, and a CEO Who Hasn’t Started Yet

Brett Shapiro -

BioNTech’s September Pivot: Seoul Data and Factory Calls Will Test Whether One Trial Halt Defines the Story

kashif hafeez -

BioNTech的“权力交接”与“临床折戟”：一场关于生存的耐力测试

Brett Shapiro -

BioNTech的“双刃一周”：肿瘤管线遇挫，疫苗业务接棒

BioNTech的“九月棋局”：当裁员重组撞上肿瘤数据的关键窗口

angelina -

BioNTech’s Sympathy Surge Masks a Structural Squeeze

Brett Shapiro -

BioNTech的转型阵痛：一边裁员重组，一边押注肿瘤未来

angelina -

BioNTech的“首尔之约”：肿瘤数据能否承接住一场“借来的行情”？

kashif hafeez -

BioNTech’s September Gauntlet: Pipeline Promises Meet a Persistent Legal Shadow

angelina -

BioNTech的“双重博弈”：专利阴影下的肿瘤叙事，能否在首尔迎来正名？

angelina -

BioNTech的“镜像行情”：对手的临床胜利，为何成了自家股价的晴雨表？

angelina -

BioNTech的“首尔时刻”：一场由对手点燃的行情，能否靠自家数据续命？

Brett Shapiro -

BioNTech的“借来的涨势”：99.8欧元的关口，是技术性过热还是新叙事起点？

angelina -
123...15Page 1 of 15